Back to News
Market Impact: 0.2
Montai Therapeutics Doses First Participants in Phase 1 Clinical Trial of MTAI-1025, a Novel Oral NRF2 Agonist for Ulcerative Colitis
Source: Business Wire
Healthcare & Biotech
Montai dosed the first participants in a Phase 1 trial of MTAI-1025, an oral NRF2 agonist being developed to treat ulcerative colitis. The milestone advances the candidate into initial human testing, but no efficacy, safety, financial, or timeline data were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- One of our most recent defensive buys cleared a hurdle and its stock jumped
- Cullinan initiates FDA filing for lung cancer drug zipalertinib
- Moderna to replace Warner Bros Discovery on Nasdaq 100
- Why McKesson Stock Soared More Than 5% Higher Today
- This biotech making precision medicines for cancer could nearly triple, says JPMorgan
- The Dow's rough month, Micron's revenue surge, Google launches Gemini 4 and more in Morning Squawk